Announcements Trials
Browse Landscape

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Conditions

Neoplasms 1905Breast Neoplasms 1426Carcinoma, Non-Small-Cell Lung 1179Prostatic Neoplasms 740Colorectal Neoplasms 686Neoplasm Metastasis 624Multiple Myeloma 548Melanoma 529Ovarian Neoplasms 456Lung Neoplasms 447Lymphoma, Non-Hodgkin 385Recurrence 374Lymphoma 374Leukemia, Myeloid, Acute 370Pancreatic Neoplasms 358Carcinoma, Renal Cell 339Carcinoma, Hepatocellular 286Stomach Neoplasms 281Leukemia, Lymphocytic, Chronic, B-Cell 268Lymphoma, Follicular 254Head and Neck Neoplasms 246Glioblastoma 220Leukemia 215Small Cell Lung Carcinoma 183Lymphoma, Large B-Cell, Diffuse 183Squamous Cell Carcinoma of Head and Neck 181Urinary Bladder Neoplasms 175Carcinoma 175Uterine Cervical Neoplasms 174Advanced Solid Tumors 161

Interventions

Piperacillin, Tazobactam Drug Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Gram-Positive Bacterial Infections × Clear all
NCT00167999 2007-03-15

Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units

Wyeth is now a wholly owned subsidiary of Pfizer

Completed
200 enrolled

Bacterial Infections, Escherichia coli Infections, Klebsiella Infections, Gram-Positive Bacterial Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡